| Autor: |
Dyall J; Integrated Research Facility, Frederick, Maryland., Johnson JC; Integrated Research Facility, Frederick, Maryland., Hart BJ; Integrated Research Facility, Frederick, Maryland., Postnikova E; Integrated Research Facility, Frederick, Maryland., Cong Y; Integrated Research Facility, Frederick, Maryland., Zhou H; Integrated Research Facility, Frederick, Maryland., Gerhardt DM; Integrated Research Facility, Frederick, Maryland., Michelotti J; Integrated Research Facility, Frederick, Maryland., Honko AN; Integrated Research Facility, Frederick, Maryland., Kern S; Bill & Melinda Gates Foundation, Seattle, Washington., DeWald LE; Integrated Research Facility, Frederick, Maryland., O'Loughlin KG; SRI International, Menlo Park, California., Green CE; SRI International, Menlo Park, California., Mirsalis JC; SRI International, Menlo Park, California., Bennett RS; Integrated Research Facility, Frederick, Maryland., Olinger GG Jr; Integrated Research Facility, Frederick, Maryland., Jahrling PB; Integrated Research Facility, Frederick, Maryland.; Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland., Hensley LE; Integrated Research Facility, Frederick, Maryland. |
| Abstrakt: |
At the onset of the 2013-2016 epidemic of Ebola virus disease (EVD), no vaccine or antiviral medication was approved for treatment. Therefore, considerable efforts were directed towards the concept of drug repurposing or repositioning. Amiodarone, an approved multi-ion channel blocker for the treatment of cardiac arrhythmia, was reported to inhibit filovirus entry in vitro. Compassionate use of amiodarone in EVD patients indicated a possible survival benefit. In support of further clinical testing, we confirmed anti-Ebola virus activity of amiodarone in different cell types. Despite promising in vitro results, amiodarone failed to protect guinea pigs from a lethal dose of Ebola virus. |
